Indication

In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

Medicine details

Medicine name:
carfilzomib (Kyprolis)
SMC ID:
SMC2290
Pharmaceutical company
Amgen Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Resubmission
Publication due date:
12 October 2020
SMC meeting date:
01 September 2020
Patient group submission deadline:
06 July 2020